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Introduction
Bone is constantly remodeled through the activities of bone-
forming  osteoblasts  and  bone-resorbing  osteoclasts  (Harada 
and Rodan, 2003; Teitelbaum and Ross, 2003). Because a rela-
tive increase of bone resorption over bone formation can result 
in osteoporosis, one of the most prevalent disorders in the aged 
population, it is important to understand the molecular mecha-
nisms regulating the differentiation and activity of osteoblasts 
and  osteoclasts  (Sambrook  and  Cooper,  2006;  Zaidi,  2007).   
Although there are already valuable therapeutic strategies to in-
hibit bone resorption in osteoporotic patients (Liberman, 2006; 
Cummings et al., 2009), it is especially required to identify ad-
ditional molecular targets on osteoblasts because clinical obser-
vations have demonstrated that the risk of skeletal fractures is 
increased in patients with dysfunctional osteoclasts, whereas it is 
decreased in states of overactivated osteoblasts, as is the case in 
individuals with osteosclerosis (Rodan and Martin, 2000). In this 
regard, it was a major breakthrough when the transmembrane 
protein LRP5 had been identified as a regulator of bone forma-
tion in humans and a possible target for osteoanabolic therapy.
LRP5, together with LRP6, is the human orthologue of 
the Drosophila melanogaster protein arrow, a coreceptor for 
wingless, the fly homologue of mammalian Wnt ligands (Wehrli 
et al., 2000). Inactivating mutations of the human LRP5 gene 
results in osteoporosis pseudoglioma syndrome, whereas acti-
vating mutations causes osteosclerosis (Gong et al., 2001; 
Boyden et al., 2002; Little et al., 2002). The key role of LRP5 
in the regulation of bone mass in humans is further underscored 
A
lthough Wnt signaling in osteoblasts is of critical 
importance for the regulation of bone remodel-
ing, it is not yet known which specific Wnt recep-
tors of the Frizzled family are functionally relevant in this 
process. In this paper, we show that Fzd9 is induced upon 
osteoblast differentiation and that Fzd9
/ mice display 
low bone mass caused by impaired bone formation. Our 
analysis  of  Fzd9
/  primary  osteoblasts  demonstrated 
defects in matrix mineralization in spite of normal expres-
sion of established differentiation markers. In contrast,   
we observed a reduced expression of chemokines and   
interferon-regulated genes in Fzd9
/ osteoblasts. We 
also  identified  the  ubiquitin-like  modifier  Isg15  as  one   
potential  downstream  mediator  of  Fzd9  in  these  cells.   
Importantly, our molecular analysis further revealed that   
canonical Wnt signaling is not impaired in the absence of 
Fzd9, thus explaining the absence of a bone resorption 
phenotype. Collectively, our results reveal a previously un-
known function of Fzd9 in osteoblasts, a finding that may 
have therapeutic implications for bone loss disorders.
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role of -catenin in the regulation of osteoclastogenesis, there 
is in vivo evidence for a negative regulation of bone formation 
by Wnt antagonists, such as Dkk1, Krm2, or Sfrp1 (Bodine   
et al., 2004; Li et al., 2006; Morvan et al., 2006; Schulze et al., 
2010). Moreover, the findings that mice carrying a hypo-
morphic mutation of Lrp6 display low bone mass and that 
polymorphisms of the human LRP6 gene have an influence on 
bone mineral density provide further evidence for a critical 
role of Wnt signaling in the control of bone remodeling, inde-
pendent of Lrp5 (Kubota et al., 2008; Sims et al., 2008). How-
ever, because both Lrp5 and Lrp6 only serve as coreceptors for 
the binding of Wnt ligands to receptors of the Frizzled (Fzd) 
family (Schulte and Bryja, 2007), it is surprising that there is 
yet no reported skeletal phenotype for a mouse model with 
impaired expression of one of the 10 known Fzd genes. In our 
opinion, it is of tremendous importance to fill this apparent 
gap in our understanding of Wnt signaling in bone cells be-
cause Fzd proteins belong to the family of serpentine recep-
tors, which represent the major class of target proteins for 
currently available drugs (Wise et al., 2002; Overington et al., 
2006). In this paper, we report that Fzd9 is the only Fzd gene 
that is differentially expressed during the early stages of osteo-
blast differentiation and that mice lacking Fzd9 display a cell-
autonomous defect of bone formation.
Results
Fzd9 expression increases during early 
osteoblast differentiation
In an attempt to identify genes whose expression increases 
during the early stages of osteoblast differentiation, we per-
formed  a  genome-wide  expression  analysis  using  GeneChip 
(Affymetrix) hybridization, thereby comparing primary osteo-
blasts derived from wild-type mice before the addition of ascor-
bate and -glycerophosphate (day 0) and 5 d thereafter (day 5). 
By sorting all genes according to their signal log ratio between 
day 0 and day 5, we observed that the expression of Fzd9 in-
creased more than twofold, and the same was the case for well-
established osteoblast differentiation markers, such as Ibsp 
(encoding  bone  sialoprotein),  Bglap  (encoding  osteocalcin), 
and Runx2 (Fig. 1 A). Because the expression of the other genes 
encoding Fzd receptors did not change between day 0 and day 5 
of differentiation, these results led us to analyze the potential 
role of Fzd9 in bone remodeling.
Before doing so, we confirmed the results obtained by 
GeneChip hybridization in independently isolated osteoblast 
cultures. This was performed by quantitative RT-PCR (qRT-
PCR; Fig. 1 B) and Western blotting (Fig. 1 C), in which we 
observed  that  the  Fzd9  mRNA  and  protein  levels  increase 
during the initial stages of osteoblast differentiation and re-
main high until day 25 of culturing, in which the extracellular 
matrix is fully mineralized. We next analyzed the expression 
pattern of Fzd9 in various tissues and cultured bone cells by 
RT-PCR, in which specific transcripts were readily detected 
in kidney, heart, eye, thyroid, bone, and cultured osteoblasts 
but not in cultured osteoclasts (Fig. 1 D). The expression in 
osteoblasts  was  finally  confirmed  by  in  situ  hybridization   
by the findings of several investigators that demonstrated an asso-
ciation of single nucleotide polymorphisms within the LRP5 
gene with decreased bone mineral density and an increased risk 
of osteoporotic fractures (Grundberg et al., 2008; Richards   
et al., 2008; van Meurs et al., 2008). Based on this cumulative 
evidence, but also because of its transmembrane localization, 
LRP5  has  been  considered  an  excellent  target  molecule  for   
osteoanabolic therapy. Moreover, because LRP5 has been sug-
gested to act as a coreceptor for ligands of the Wnt family (Mao 
et al., 2001), it appeared reasonable to speculate that Wnt sig-
naling in osteoblasts is physiologically involved in the control 
of bone formation.
One way to address this issue was the cell type–specific 
inactivation of -catenin, whose stabilization and entry into the 
nucleus is the key step in the canonical Wnt signaling pathway 
(Wodarz and Nusse, 1998). Consistent with the expected re-
quirement of this pathway for osteoblast differentiation, it has 
been demonstrated that an inactivation of -catenin in mesen-
chymal progenitor cells causes an arrest of osteoblast differen-
tiation and defects of skeletal development (Day et al., 2005, 
Hill et al., 2005; Hu et al., 2005). Unexpectedly however, when 
-catenin was specifically inactivated in mature osteoblasts or 
in terminally differentiated osteocytes, a low bone mass pheno-
type was observed, which was not caused by decreased bone 
formation but by activated bone resorption (Glass et al., 2005; 
Holmen et al., 2005; Kramer et al., 2010). Because the opposite 
phenotype was observed upon osteoblast-specific activation of 
-catenin, it is now commonly accepted that the canonical Wnt 
signaling pathway in osteoblasts primarily controls bone re-
sorption, which is molecularly explained by an effect on the ex-
pression of Tnfrsf11b, the gene encoding the osteoclastogenesis 
inhibitor osteoprotegerin (Opg; Glass et al., 2005).
Because Lrp5 deficiency in mice and humans specifically 
affects bone formation (Gong et al., 2001; Kato et al., 2002), 
these results further suggested that Lrp5 has no influence on ca-
nonical Wnt signaling in osteoblasts. This has been demonstrated 
by the finding that mice specifically lacking Lrp5 in osteoblasts do 
not display a bone-remodeling phenotype, whereas a specific 
deletion of Lrp5 in the duodenum causes decreased bone forma-
tion (Yadav et al., 2008). The molecular explanation for this in-
direct influence of Lrp5 on bone mass lies in the regulation of 
serotonin production in enterochromaffin cells, in which Lrp5 
negatively regulates the expression of Tph1, the rate-limiting 
enzyme of peripheral serotonin synthesis. As a result, serotonin 
levels are increased in the absence of Lrp5, thereby causing low 
bone formation because gut-derived serotonin has a negative   
effect on osteoblast proliferation (Yadav et al., 2008). While   
increased circulating serotonin levels have also been observed in 
individuals with osteoporosis pseudoglioma syndrome, reduced 
levels  were  found  in  carriers  of  LRP5-activating  mutations, 
thereby confirming that the mouse observations are also relevant 
in humans (Frost et al., 2010; Ramirez Rodriguez et al., 2010; 
Saarinen et al., 2010).
Although these results have demonstrated that Lrp5 con-
trols bone mass through a different mechanism, there is still 
hallmark evidence for a direct influence of Wnt signaling in 
osteoblasts on bone remodeling. Despite the aforementioned 1059 Fzd9 and bone formation • Albers et al.
Fzd9-deficient mice display osteopenia 
caused by decreased bone formation
Because we did not observe defects of skeletal development in 
mice lacking Fzd9, we went on to perform nondecalcified his-
tology of the spine at the ages of 6, 24, and 52 wk. Here, we 
found no significant difference between wild-type and Fzd9
/ 
littermates at 6 wk of age, but thereafter, bone mass was largely 
using tibiae from wild-type and Fzd9
/ mice, in which we 
found Fzd9 transcripts only in the primary spongiosa and the 
bone collar region of wild-type sections (Fig. 1 E). Collec-
tively, these findings led us to analyze the skeletal phenotype 
of Fzd9
/ mice, which have been described to display no 
major abnormalities besides a defect of B cell differentiation 
(Ranheim et al., 2005).
Figure 1.  Expression of Fzd9 in osteoblasts. (A) Ranking of the genes with the strongest induction of expression between day 0 (d0) and day 5 (d5) of 
primary osteoblast differentiation. Given are the signal intensities (Affymetrix) for both time points and the signal log ratios (SLR). (B) qRT-PCR for Fzd9 
and Ibsp expression between day 0 and day 25 of primary osteoblast differentiation. Error bars represent means ± SD (n = 3). (C) Western blot confirm-
ing the presence of Fzd9 in primary osteoblasts. (D) RT-PCR analysis of Fzd9 expression in various tissues and primary bone cells (Ocl, osteoclast;   
Obl, osteoblast). (E) In situ hybridization in tibia sections from 3-d-old wild-type (Fzd9
+/+) and Fzd9-deficient (Fzd9
/) mice showing Fzd9 expression in 
the primary spongiosa (PS) and the bone collar (BC) region but not in the growth plate (GP). Bars, 200 µm. Black lines indicate that intervening lanes have 
been spliced out.JCB • VOLUME 192 • NUMBER 6 • 2011   1060
also causes persistent embryonic eye vascularization, we next 
analyzed vascular regression in Fzd9
/ mice at day 4 and day 10 
after birth (Fig. 2 C). Unlike the case in Lrp5-deficient mice, we 
did observe a postnatal decrease in the number of hyaloid ves-
sels in Fzd9
/ animals, thereby ruling out an additional pheno-
type associated with the Fzd9 inactivation (Fig. 2 D).
affected by the absence of Fzd9 (Fig. 2 A). In fact, histomorpho-
metric quantification of the trabecular bone volume revealed a 
reduction in Fzd9
/ vertebral bodies by 35 and 40% at the ages 
of 24 and 52 wk, respectively, which was mostly attributed to a 
lower trabecular number, whereas trabecular thickness was only 
moderately affected (Fig. 2 B). Because the deficiency of Lrp5 
Figure 2.  Osteopenia in Fzd9-deficient mice. (A) von Kossa/van Gieson staining of nondecalcified sections from vertebral bodies of wild-type and 
Fzd9
/ mice at the indicated ages. Bars, 1 mm. (B) Histomorphometric quantification of the trabecular bone volume per tissue volume (BV/TV), the tra-
becular number (Tb.N.), and the trabecular thickness (Tb.Th.) in wild-type (white bars) and Fzd9
/ (black bars) mice. (C) Hematoxylin/eosin staining of 
eyeballs from 4-d-old (P4) and 10-d-old (P10) wild-type, Fzd9
/, and Lrp5
/ mice. Bars, 250 µm. (D) Quantification of hyaloid vessels. All error bars 
represent means ± SD (n = 6). Asterisks indicate statistically significant differences (P < 0.05).1061 Fzd9 and bone formation • Albers et al.
This  was  subsequently  confirmed  by  histomorphometry,  in 
which we found no change in the numbers of osteoclasts per 
bone surface (Fig. 3 D). Thus, it appears that the significant re-
duction of bone-specific collagen degradation products found in 
the serum of Fzd9
/ mice is rather the consequence of their 
decreased bone volume.
To confirm the deduced hypothesis that the osteopenia of 
Fzd9
/ mice is primarily caused by a cell-autonomous defect 
of bone formation, we next isolated bone marrow stromal cells 
from wild-type and Fzd9
/ littermates and differentiated them 
by adding ascorbate and -glycerophosphate. By performing 
alizarin red staining with subsequent quantification, we were 
able to demonstrate a decreased mineralization of Fzd9
/ cells 
ex vivo (Fig. 3 E). In contrast, when we differentiated bone marrow 
To uncover the cellular basis of the osteopenia observed 
in Fzd9
/ mice, we next determined the histomorphometric 
parameters of bone formation and bone resorption. After dual 
injection of calcein, a fluorescent dye that binds to newly formed 
bone, we were able to demonstrate that bone formation was 
largely decreased in Fzd9
/ mice, as illustrated by a lower 
number of calcein-labeled surfaces but also by a reduced dis-
tance between the two labeling fronts at sites of double labeling 
(Fig. 3 A). Likewise, when we quantified the osteoblast number 
and bone formation rate, we observed a 30 and 45% reduction, 
respectively, in 24-wk-old Fzd9
/ mice (Fig. 3 B). In contrast, 
when we performed tartrate-resistant acid phosphatase (TRAP) 
activity staining of osteoclasts, we did not find a significant dif-
ference between wild-type and Fzd9
/ littermates (Fig. 3 C). 
Figure 3.  Decreased bone formation rate in Fzd9-deficient mice. (A) Fluorescent micrographs of vertebral body sections from 24-wk-old wild-type and 
Fzd9
/ mice reveal a reduced number of calcein-labeled surfaces and a smaller distance between labeling fronts in the latter ones. Bars: (top) 1 mm; 
(bottom) 20 µm. (B) Histomorphometric quantification of the osteoblast number per bone perimeter (Ob.N/B.Pm) and the bone formation rate per bone 
surface (BFR/BS). (C) TRAP activity staining of osteoclasts reveals no difference between 24-wk-old wild-type and Fzd9-deficient littermates. Bars, 50 µm. 
(D) Histomorphometric quantification of the osteoclast number per bone perimeter and concentrations of collagen degradation products (CrossLaps) in the 
serum. (B and D) n = 6. (E) Alizarin red staining of bone marrow cells differentiated into osteoblasts for 10 d and quantification of the mineralized area.   
(F) Quantification of the number of TRAP-positive multinucleated (MNC) osteoclasts differentiated from bone marrow precursor cells of wild-type and Fzd9
/ 
mice. (E and F) n = 3. Error bars represent means ± SD. Asterisks indicate statistically significant differences (P < 0.05).JCB • VOLUME 192 • NUMBER 6 • 2011   1062
Figure 4.  Cell-autonomous defect of Fzd9-deficient osteoblasts. (A) BrdU incorporation assay using wild-type and Fzd9
/ primary osteoblasts. n = 8.   
(B) von Kossa staining of the mineralized matrix reveals a cell-autonomous defect of bone formation in Fzd9
/ osteoblasts. (C) Quantification of the aliza-
rin red incorporation in wild-type and Fzd9
/ primary osteoblasts at the indicated stages of differentiation. (D) Normal expression of known osteoblast 1063 Fzd9 and bone formation • Albers et al.
We  further  performed  a  comparative  Western  blot  analysis   
using untreated wild-type and Fzd9
/ osteoblasts at day 10 of 
differentiation. Here, we confirmed the normal expression of 
Axin2 and Opg, and we also detected no difference in the pro-
tein levels of Gsk3- (Fig. 4 H). In contrast, we found de-
creased  levels  of  phosphorylated  Erk1/2  in Fzd9
/  cells, 
whereas there was no difference in the protein levels of the 
parathyroid hormone receptor or of ATF4, whose presence in 
osteoblasts  is  primarily  controlled  posttranslationally  (Yang 
and Karsenty, 2004).
Decreased expression of chemokines  
and interferon-regulated genes in  
Fzd9-deficient osteoblasts
To further elucidate the molecular defects of Fzd9
/ osteo-
blasts, we next focused on the genes that displayed a more 
than twofold reduction of expression levels compared with 
wild-type cultures. Although none of these genes, at least at 
first sight, provided a reasonable explanation for the decreased 
bone formation caused by Fzd9 deficiency, it was striking 
that there were two groups of genes whose expression ap-
peared to be regulated by Fzd9, namely interferon-regulated 
genes and genes encoding chemokines (Fig. 5 A). To address 
the possible relevance of these findings, we first performed 
qRT-PCR for three members of both groups and observed a 
significantly reduced expression of Oasl2, Isg15, Ifit1, Ccl5, 
Cxcl5, and Ccl2 in primary osteoblasts from Fzd9
/ mice 
(Fig. 5 B). To analyze whether this is also the case in vivo, we 
performed the same experiments with cDNA derived from 
femora of wild-type and Fzd9
/ mice and obtained similar 
results (Fig. 5 C).
Because the Fzd9 deficiency did not impair canonical 
Wnt signaling, we next addressed the question of whether the 
genes with lower expression rates in Fzd9
/ osteoblasts were 
direct targets of Wnt5a, which is known to induce noncanoni-
cal signaling pathways. This was again assessed by qRT-PCR 
after a treatment of wild-type osteoblasts with either Wnt3a or 
Wnt5a for 6 h. Here, we found that Wnt5a did not stimulate 
the expression of Axin2 and Apccd1, as expected, whereas it 
specifically induced the expression of the chemokine-encoding 
genes (Fig. 5 D). In contrast, there was no effect of either Wnt 
ligand  on  the  expression  of  the  interferon-regulated  genes, 
whereas the expression of Stat1, encoding a key transcription 
factor  in  interferon-dependent  signaling  (Trinchieri,  2010), 
was induced by Wnt5a (Fig. 5 D). Because we further ob-
served that Wnt5a induced Erk1/2 and Akt phosphorylation in 
wild-type  osteoblasts,  we  next  treated  serum-starved  wild-
type and Fzd9
/ cells with Wnt5a for 30 min and then per-
formed Western blotting to quantify the differences. Here, we 
found that the Wnt5a-induced phosphorylation of Erk1/2 and 
precursor cells into osteoclasts, there was no significant differ-
ence in the number of TRAP-positive multinucleated cells be-
tween wild-type and Fzd9
/ cultures (Fig. 3 F).
The cell-autonomous defect of Fzd9-
deficient osteoblasts is not associated with 
impaired canonical Wnt signaling
Because  bone  marrow–derived  osteoblast  cultures  contain  a 
higher percentage of other cell types compared with calvaria-
derived osteoblasts, we next isolated the primary cells from the 
calvariae of newborn mice to address the question of whether 
these Fzd9
/ cells would also display a cell-autonomous defect 
ex vivo. In the first set of experiments, we cultured the osteo-
blasts for 5 d in the presence of ascorbate and -glycerophosphate 
and monitored their proliferation rate by BrdU incorporation 
assays. Here, we observed a transient decrease in Fzd9
/ cul-
tures at day 2 of differentiation, thereby providing the first evi-
dence for an intrinsic defect (Fig. 4 A). The second evidence 
came from a longer differentiation period, in which we analyzed 
the matrix mineralization of wild-type and Fzd9
/ osteoblasts 
after 10, 15, and 20 d of culturing using von Kossa staining   
(Fig. 4 B). Here, we found that Fzd9
/ cultures mineralized poorly 
until day 15 of differentiation and that the amount of mineral-
ized matrix, again assessed by alizarin red staining, was largely 
decreased compared with wild-type cultures also after 20 d of 
differentiation (Fig. 4 C). To uncover the molecular basis of this 
cellular defect, we next isolated RNA from wild-type and 
Fzd9
/ cultures at day 10 of differentiation and subjected it to 
comparative GeneChip hybridization. Here, we first focused on 
the expression levels of several osteoblast differentiation mark-
ers, but we failed to detect differences between wild-type and 
Fzd9
/ cultures that were higher than twofold (Fig. 4 D). The 
same was the case for known target genes of the canonical Wnt 
signaling pathway, such as Tnfrsf11b, Axin2, and Apcdd1 (Jho 
et al., 2002; Jukkola et al., 2004; Glass et al., 2005). To confirm 
these  findings,  we  performed  qRT-PCR  using  independently 
isolated cultures, in which we found no significant changes in 
the expression of Alpl, Ibsp, or Tnfrsf11b (Fig. 4 E).
To address the question of whether Fzd9
/ osteoblasts 
display a defect of canonical Wnt signaling, we next treated 
wild-type and Fzd9
/ cultures at day 10 of differentiation with 
recombinant Wnt3a for 6 h and thereafter monitored gene ex-
pression by qRT-PCR (Fig. 4 F). Here, we observed that the ex-
pression of the Wnt target genes Axin2 and Apcdd1 was induced 
to the same extent in wild-type and Fzd9
/ cells, thus demon-
strating intact canonical Wnt signaling in the absence of Fzd9. 
This was also confirmed using Western blotting in which we 
observed that both the phosphorylation of Lrp6 and the reduced 
levels  of  phosphorylated  -catenin,  induced  by  stimulation 
with Wnt3a, were not impaired by the absence of Fzd9 (Fig. 4 G). 
differentiation markers and Wnt target genes in Fzd9
/ osteoblasts. Given are the signal intensities (Affymetrix) for wild-type and Fzd9
/ osteoblasts 
at day 10 (d10) of differentiation and the signal log ratios (SLR). (E) qRT-PCR expression analysis for the indicated genes in wild-type and Fzd9
/ osteo-
blasts. (F) qRT-PCR expression analysis for the indicated genes in wild-type and Fzd9
/ osteoblasts after a 6-h stimulation by Wnt3a. (C, E, and F) n = 3.   
(G) Western blotting with the indicated antibodies demonstrates that canonical Wnt signaling is unaffected in Fzd9
/ osteoblasts. Molecular mass markers 
represent kilodaltons. (H) Western blotting with the indicated antibodies demonstrates decreased Erk1/2 phosphorylation in Fzd9
/ osteoblasts. Error 
bars represent means ± SD. Asterisks indicate statistically significant differences (P < 0.05). Black lines indicate that intervening lanes have been spliced out.
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Figure 5.  Decreased expression of chemokines and interferon-regulated genes in Fzd9
/ osteoblasts. (A) Signal intensities (Affymetrix) and signal log 
ratios for wild-type and Fzd9
/ osteoblasts at day 10 of differentiation. Besides Fzd9 itself, genes either encode chemokines (Cclx and Cxclx) or have 
been identified as interferon regulated (Oasl2, Ifix, Isg15, Ligp2, and Irfx). Genes highlighted in red displayed a signal log ratio (SLR) >2.0 in the initial 
GeneChip experiment shown in Fig. 1 A. (B) qRT-PCR expression analysis for the indicated genes in wild-type and Fzd9
/ osteoblasts. (C) qRT-PCR expres-
sion analysis for the indicated genes in wild-type and Fzd9
/ femora. (D) qRT-PCR expression analysis for the indicated genes in wild-type osteoblasts 
treated for 6 h with Wnt3a or Wnt5a. (E) Western blotting with the indicated antibodies demonstrates decreased Erk1/2 and Akt phosphorylation in 
Fzd9
/ osteoblasts. The relative changes of the ratios between the phosphorylated and nonphosphorylated forms are given on the bottom. (F) qRT-PCR   
expression analysis and Western blotting demonstrate decreased Stat1 expression in Fzd9
/ osteoblasts. (G) qRT-PCR expression analysis for the indicated 
genes in wild-type and Fzd9
/ osteoblasts after a 6-h stimulation by Ifn- or Ifn-. Error bars represent means ± SD (n = 3). Asterisks represent statistically 
significant differences (P < 0.05). Black lines indicate that intervening lanes have been spliced out.1065 Fzd9 and bone formation • Albers et al.
The ubiquitin-like modifier Isg15 is involved 
in the regulation of bone formation
Given the striking defect of osteoblastogenesis caused by the 
absence of Fzd9, it would surely be interesting to analyze the 
role of each of its potential downstream regulators in future   
experiments. However, because Isg15, one of the interferon- 
regulated genes with decreased expression in Fzd9
/ osteoblasts, 
has recently gained a lot of attention, as it encodes a ubiquitin-
like modifier protein (Loeb and Haas, 1992; Skaug and Chen, 
2010), we went on to address the potential relevance of Isg15 in 
the regulation of bone formation. Using qRT-PCR, we first con-
firmed that Isg15 expression levels increase during the early 
stages of osteoblast differentiation (Fig. 6 A). We then per-
formed Western blotting using an Isg15-specific antibody and 
did not only observe an increase of free Isg15 during the differ-
entiation process but also of ISGylated proteins (Fig. 6 B).   
In addition, we found that the ISGylation of specific proteins 
was less pronounced in Fzd9
/ cells at day 5 of differentiation 
(Fig. 6 C). We next addressed the question of whether the 
Akt was less pronounced in Fzd9
/ cells, thereby providing 
evidence for impaired noncanonical Wnt signaling in the ab-
sence of Fzd9 (Fig. 5 E).
Although we can only speculate so far on the relevance of 
the decreased chemokine expression in the absence of Fzd9, we 
followed up on the interferon-regulated genes because five of 
them (Fig. 5 A, highlighted in red) were found to display a signal 
log ratio >2.0 in our initial GeneChip hybridization comparing 
wild-type primary osteoblasts at day 0 and day 5 of differentia-
tion. Because the same was the case for Stat1, we first confirmed 
its reduced expression in Fzd9
/ osteoblasts by qRT-PCR but 
also on the protein level using Western blotting (Fig. 5 F). To ana-
lyze whether the reduced levels of Stat1 in Fzd9
/ osteoblasts 
would impair interferon-dependent signaling, we next treated 
wild-type and Fzd9
/ osteoblasts with Ifn- and Ifn- for 6 h 
before we monitored gene expression by qRT-PCR. Here, we 
found that both ligands induced the expression of Oasl2, Isg15, 
and Ifit1 in wild-type osteoblasts and that this effect was signifi-
cantly reduced in Fzd9
/ cultures (Fig. 5 G).
Figure 6.  Protein ISGylation in osteoblasts. (A) qRT-PCR expression analysis for Isg15 at different stages of primary osteoblast differentiation. Error bars 
represent means ± SD (n = 3). (B) Western blotting with an Isg15-specific antibody demonstrating an increase of free Isg15 (arrow) and ISGylated proteins 
during differentiation of wild-type osteoblasts. (C) Decreased ISGylation of specific proteins (arrowheads) in Fzd9
/ osteoblasts at day 5 (d5) of dif-
ferentiation. (D) von Kossa staining of mineralized matrix in wild-type and Fzd9
/ osteoblasts at day 10 of differentiation. Fzd9
/ cultures were either 
transduced with an empty (mock) or an Isg15-encoding retroviral vector as indicated. Quantification of the mineralized area is given on the bottom. Values 
represent means ± SD (n = 3). The asterisk represents a statistically significant difference to untreated cells (P < 0.05). Black lines indicate that intervening 
lanes have been spliced out.JCB • VOLUME 192 • NUMBER 6 • 2011   1066
Figure 7.  Decreased bone formation in Isg15-deficient mice. (A) von Kossa/van Gieson staining of nondecalcified sections of vertebral bodies from 
24- and 52-wk-old wild-type and Isg15
/ mice. Bars, 1 mm. (B) Histomorphometric quantification of the trabecular bone volume at the indicated ages. 
BV/TV, bone volume per tissue volume. (C) Fluorescent micrographs reveal a reduced distance between the calcein-labeling fronts in 24-wk-old Isg15
/ mice. 1067 Fzd9 and bone formation • Albers et al.
that both Fzd9
+/ and Fzd9
/ mice display a reduced trabecular 
bone volume, a lower number of osteoblasts, and a decreased 
bone  formation  rate  compared  with  wild-type  littermates 
(Fig. 8 C). Because one of the individuals with WBS had a his-
tory of three fractures within the thoracic and lumbar spine 
(Fig. 8 D), we further performed biomechanical testing of the 
mouse bones, in which we observed a decreased biomechanical 
competence of Fzd9
+/ and Fzd9
/ vertebral bodies and femora 
(Fig. 8 E). Collectively, these latter findings underscore the rel-
evance of Fzd9 for the regulation of bone remodeling in mice and 
raise the hypothesis that the osteopenia associated with WBS is 
explained, at least in part, by FZD9 haploinsufficiency.
Discussion
FZD9 was first identified in 1997 and immediately gained a lot 
of attention because it is located on chromosome 7q11.23 within 
the region, whose hemizygous deletion causes WBS, a neuro-
developmental disorder associated with multiple additional mani-
festations (Wang et al., 1997; Schubert, 2009). To analyze the 
potential contribution of a FZD9 deletion to the pathogenesis of 
WBS, the murine Fzd9 gene was cloned 2 yr later and found 
expressed in a variety of tissues (Wang et al., 1999). The func-
tional relevance of Fzd9 was subsequently analyzed through the 
generation of two different mouse deficiency models, both de-
leting the entire open reading frame (Ranheim et al., 2005; Zhao 
et al., 2005a). Not necessarily expected, Fzd9
/ mice devel-
oped normally, were fertile, and did not display any gross 
abnormalities. However, whereas one of the studies revealed 
hippocampal defects and learning deficits in Fzd9
/ mice 
(Zhao et al., 2005a), the other study did not detect obvious fea-
tures of WBS in their mice, although they displayed abnormal   
B cell development (Ranheim et al., 2005). Because a skeletal 
analysis of both mouse models has not been reported elsewhere, 
the data presented in our manuscript provide the first evidence 
for a physiological role of Fzd9 as a regulator of bone formation. 
In addition, they are the first to demonstrate a functional role for 
one the Fzd family members in bone remodeling, which is im-
portant for our understanding of Wnt signaling in osteoblasts.
Given the fact that the bone formation phenotype of 
Fzd9
/ mice is caused by a cell-autonomous osteoblast defect, 
we were further able to analyze some of the molecular mecha-
nisms underlying the observed phenotype. Here, we found that, 
although Fzd9 has previously been shown to activate -catenin–
dependent gene expression in 293T cells (Karasawa et al., 2002), 
canonical Wnt signaling was not impaired in Fzd9
/ osteo-
blasts, which is in full agreement with the absence of a bone   
formation phenotype in mice with altered -catenin signaling in 
restoration of Isg15 expression in Fzd9
/ osteoblasts would 
rescue their defect of matrix mineralization. For that purpose, 
we transduced these cells at a nondifferentiated stage with an 
Isg15-expressing retrovirus and quantified the mineralized area 
at day 10 of differentiation. Here, we found a significant in-
crease compared with mock-transfected cells, thus suggesting 
that Isg15 is one downstream effector of Fzd9 in osteoblasts 
(Fig. 6 D).
To analyze the role of Isg15 in bone remodeling in vivo, 
we took advantage of an Isg15-deficient mouse model, which 
has been described to display no obvious phenotype outside the 
skeleton (Osiak et al., 2005). Using nondecalcified histology of 
the spine (Fig. 7 A), we were able to demonstrate that the tra-
becular bone volume is significantly decreased in 24- and 52-
wk-old  Isg15
/  mice  compared  with  wild-type  littermates   
(Fig. 7 B). As is the case in Fzd9
/ mice, this phenotype is 
caused by decreased bone formation, which was assessed by 
cellular and dynamic histomorphometry (Fig. 7 C). In contrast, 
neither the number of osteoclasts nor their resorptive activity 
was affected by the absence of Isg15 (Fig. 7 D). We further   
analyzed the cortical bone of the femora from wild-type and 
Isg15
/ mice and did not only observe a reduced cortical thick-
ness in the latter ones (Fig. 7 E) but also a decreased biome-
chanical stability in three point–bending assays (Fig. 7 F). 
Likewise, the force until bone failure was reduced in Isg15
/ 
L6 vertebral bodies that were subjected to microcompression 
testing. Finally, we isolated bone marrow cells from wild-type 
and Isg15
/ mice and analyzed their ability to differentiate into 
osteoblasts and osteoclasts. Here, we obtained similar results as 
we did for Fzd9
/ cells, namely reduced mineralization after 
differentiation into osteoblasts (Fig. 7 G) but normal osteoclasto-
genesis (Fig. 7 H).
Low bone mass caused by  
Fzd9 heterozygosity
Because FZD9 is one of the genes whose hemizygous deletion 
in humans causes Williams–Beuren syndrome (WBS; Wang   
et al., 1997; Schubert, 2009) and because we have previously 
reported that individuals suffering from WBS display decreased 
bone mineral density (Cherniske et al., 2004), we finally ad-
dressed the question of whether Fzd9
+/ mice would also dis-
play a low bone mass phenotype. For that purpose, we performed 
nondecalcified histology and microcomputed tomography (µCT) 
scanning of the spines from 70-wk-old wild-type, Fzd9
+/, and 
Fzd9
/ mice and observed osteopenia in the two latter groups 
(Fig. 8 A). Likewise, using cross-sectional µCT scanning, we 
observed a reduced cortical thickness of Fzd9
+/ and Fzd9
/ 
femora (Fig. 8 B). Histomorphometric quantification revealed 
Bars, 20 µm. The histomorphometric quantification of the osteoblast surface per bone surface (ObS/BS) and the bone formation rate is given on the bot-
tom. (D) Histomorphometric quantification of the osteoclast surface per bone surface and concentrations of collagen degradation products in the serum.   
(E) Cross-sectional µCT scanning of the femora from of 24-wk-old wild-type and Isg15
/ mice. Bars, 500 µm. Quantifications of the cortical thickness 
(C.Th.) are given on the bottom. (F) Three point–bending assays of femora and microcompression testing of vertebral body L6 (spine) reveals that the force 
until bone failure (Fmax) is decreased in Isg15
/ mice. (B–D and F) n = 6. (G) Alizarin red staining of bone marrow cells differentiated into osteoblasts 
for 10 d and quantification of the mineralized area. (H) Quantification of the number of TRAP-positive multinucleated (MNC) osteoclasts differentiated from 
bone marrow precursor cells of wild-type and Isg15
/ mice. (G and H) n = 3. Error bars represent means ± SD. Asterisks indicate statistically significant 
differences (P < 0.05).
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Figure 8.  Heterozygosity of Fzd9 causes osteopenia. (A) von Kossa/van Gieson staining of nondecalcified sections and µCT scanning of vertebral bodies 
from 70-wk-old wild-type, Fzd9
+/, and Fzd9
/ mice. Bars, 1 mm. (B) Cross-sectional µCT scanning of femora. Bars, 500 µm. Quantifications of the 
cortical thickness (C.Th.) are given on the bottom. (C) Histomorphometric quantification of the trabecular bone volume, the osteoblast number, and the 
bone formation rate. BV/TV, bone volume per tissue volume; Ob.N/B.Pm, osteoblast number per bone perimeter; BFR/BS, bone formation rate per bone 
surface. (D) X rays of the spine from an individual with WBS and osteoporosis. Bars, 10 cm. Note the fractures of vertebral bodies (arrows), one of them 
being surgically stabilized. (E) Microcompression testing of the spine and three point–bending assays of femora demonstrate a decreased biomechanical 
stability of Fzd9
+/ and Fzd9
/ bones. Fmax, force until bone failure. Error bars represent means ± SD (n = 6). Asterisks represent a statistically significant 
difference (P < 0.05).1069 Fzd9 and bone formation • Albers et al.
mice and observed osteopenia caused by decreased bone forma-
tion. In addition, we found that the cell-autonomous defect of 
Fzd9
/ osteoblasts is at least partially rescued after transduc-
tion of an Isg15 retrovirus, thus suggesting that Isg15 is one of 
the relevant downstream targets of Fzd9 in the regulation of 
bone formation. Although we could further demonstrate a cell-
autonomous defect of osteoblast differentiation caused by Isg15 
deficiency, we were not yet able to identify the underlying mecha-
nisms, which is best explained by the paucity of knowledge regard-
ing the physiological role of Isg15 (Skaug and Chen, 2010).
Isg15 was identified as an interferon-induced gene with a 
molecular mass of 15 kD, which can be conjugated to target 
proteins  in  a  three-step  enzymatic  cascade. Although  this   
ISGylation process is similar to the conjugation of ubiquitin, 
Isg15 apparently does not influence proteasomal degradation 
but rather affects the function of its target proteins, similar   
to other posttranslational modifications (Okumura et al., 2007; 
Jeon et al., 2009; Shi et al., 2010). However, because proteomics 
studies have identified >300 potential target proteins and be-
cause recent evidence has suggested that Isg15 broadly targets 
newly synthesized proteins, it is difficult to address the question 
which of these ISGylated proteins are functionally relevant in 
osteoblasts (Zhao et al., 2005b; Durfee et al., 2010). In this re-
gard, it is important to state that the observed osteopenia is the 
only spontaneously developing phenotype of Isg15
/ mice de-
scribed so far. This implies that a thorough molecular compari-
son of wild-type and Isg15
/ osteoblasts could provide novel 
insights into the physiological role of Isg15, although this 
analysis is certainly beyond the scope of our manuscript.
Regardless of these open questions, we believe that the 
most relevant hypothesis raised by our study is that FZD9 might 
be involved in the regulation of bone formation in humans. To 
our knowledge, no FZD9 mutations have been reported in indi-
viduals with bone loss disorders, yet it is tempting to speculate 
that the low bone mass in WBS individuals may be the conse-
quence of their hemizygous deletion of the FZD9 gene. To address 
this issue, we have performed dual x-ray energy absorptiometry 
in 15 individuals with WBS, aged between 30 and 50 yr, in 
which we found a mean T score below 1.0 in three different 
skeletal elements, which is indicative of osteopenia (unpub-
lished data). Moreover, four of these individuals were diagnosed 
with osteoporosis (T score below 2.5), and one of them dis-
played fractures within the thoracic and lumbar spine. Although 
it is virtually impossible to prove that the reduced bone mineral 
density in WBS individuals is caused by FZD9 haploinsuffi-
ciency, there are at least two arguments derived from mouse ex-
periments in favor of this hypothesis. First, among all the genes 
located in the WBS deletion region, Fzd9 was the only one that 
is differentially expressed during primary osteoblast differentia-
tion. Second, the loss of one Fzd9 allele in mice resulted in 
osteopenia and reduced bone formation, and there were no sta-
tistically significant differences in our skeletal analysis between 
Fzd9
+/ and Fzd9
/ mice at 70 wk of age.
Thus, based on these findings, we concur with our previ-
ous  recommendation  that  bone  densitometry  should  be  rou-
tinely performed in individuals with WBS (Cherniske et al., 
2004) because some percentage of them may benefit from one 
osteoblasts (Glass et al., 2005; Holmen et al., 2005; Kramer et al., 
2010). In fact, both the low bone mass phenotype of mice lack-
ing -catenin in osteoblasts and the osteopetrosis of mice ex-
pressing a stabilized form of -catenin in osteoblasts are fully 
explained by impaired Tnfrsf11b expression, thereby triggering 
changes of osteoclast differentiation and bone resorption. Thus, 
because we neither observed decreased Tnfrsf11b expression 
nor increased bone resorption in Fzd9
/ mice, it appears that 
Fzd9 rather affects other signaling pathways. In addition, our 
findings further demonstrate that Fzd9 does not influence bone 
formation through an interaction with Lrp5 because Lrp5
/  
osteoblasts do not display a cell-autonomous defect (Yadav 
et al., 2008) and because serotonin levels are normal in the 
serum of Fzd9
/ mice (unpublished data).
To understand the defect of Fzd9
/ osteoblasts at the mo-
lecular level, we further performed a comparative genome-wide 
expression analysis using GeneChip hybridization. Here, we 
did not observe striking differences in the expression of several 
well-established osteoblast differentiation markers and canoni-
cal Wnt-signaling target genes between wild-type and Fzd9- 
deficient cultures, but we did observe a reduced expression of 
chemokines and interferon-regulated genes in the latter ones. 
By treating wild-type osteoblasts with Wnt3a or Wnt5a, we 
were further able to demonstrate that the chemokine-encoding 
genes were direct targets of Wnt5a, which suggested that non-
canonical Wnt signaling pathways could be impaired in Fzd9
/ 
osteoblasts. This was confirmed by Western blotting, in which 
we found that the known effects of Wnt5a on Erk1/2 and Akt 
phosphorylation (Almeida et al., 2005; Kawasaki et al., 2007; 
Peng et al., 2010) were essentially blunted in Fzd9
/ cells. 
Collectively, these results suggest that the presence of Fzd9 in 
osteoblasts is required to induce noncanonical Wnt signaling 
pathways, and they are in full agreement with the positive influ-
ence of increased Erk and Akt signaling on bone formation 
(Ford-Hutchinson et al., 2007; Ge et al., 2007). Whether an im-
paired expression of chemokines is involved in these effects re-
mains to be established, and for now, we can only speculate 
about the possibility that their decreased expression in osteo-
blasts contributes to the low bone mass phenotype of Fzd9-
deficient mice.
In contrast to the effect of Wnt5a on the expression of 
Ccl5, Cxcl5, and Ccl2, there was no direct influence of Wnt   
ligands on the expression of Oasl2, Isg15, and Ifit1. However, 
because Wnt5a did induce the expression of Stat1, it appears 
that the decreased expression of interferon-regulated genes in 
Fzd9
/ osteoblasts is the consequence of their reduced Stat1 
protein levels. Consistent with this notion, we found that the   
expression of interferon-regulated genes is induced during the 
early  differentiation  stages  of  wild-type  osteoblasts  together 
with the expression of Stat1 and Fzd9. In this paper, we have 
focused on one of these genes, Isg15, which appeared to be par-
ticularly interesting because it encodes a ubiquitin-like modifier 
protein and because the regulation of protein degradation has 
been demonstrated to be of critical importance for osteoblast 
activity (Yang and Karsenty, 2004; Jones et al., 2006). Triggered 
by the finding that protein ISGylation is reduced in Fzd9
/ osteo-
blasts, we embarked on the phenotypic analysis of Isg15
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GE Healthcare). Membranes were blocked for 1 h using blocking buffer 
(TBS containing 0.1% Tween 20 and 5% nonfat dry milk) and incubated 
with primary antibody at a dilution of 1:1,000 at 4°C overnight. The anti-
bodies  were  directed  against  Fzd9  (AF2440;  R&D  Systems),  -actin 
(MAB1501; Millipore), phospho-Lrp6 (2568; Cell Signaling Technology), 
phospho–-catenin  (9561;  Cell  Signaling  Technology),  total  -catenin 
(9582; Cell Signaling Technology), axin-2 (ab32197; Abcam), Opg 
(AF459; R&D Systems), phospho–Gsk3- (9336; Cell Signaling Technol-
ogy), Gsk3- (9315; Cell Signaling Technology), phospho-Erk1/2 (9101; 
Cell Signaling Technology), Erk1/2 (4695; Cell Signaling Technology), 
Pthr1 (05-517; Millipore), Atf4 (WH0000468M1; Sigma-Aldrich), p-Akt 
(4060; Cell Signaling Technology), Akt (9272; Cell Signaling Technology), 
Stat1 (9172; Cell Signaling Technology), and Isg15 (Osiak et al., 2005). 
Washing steps were performed with TBS containing 0.1% Tween 20. Sec-
ondary  HRP-conjugated  antibodies  (Dako)  were  used  at  a  dilution  of 
1:2,000. Image acquisition was performed using a photoscanner (Scanjet 
G4050; Hewlett-Packard). Quantification was performed using a gel docu-
mentation system (ChemiDoc XRS; Bio-Rad Laboratories).
Mice
Fzd9-deficient mice (129/Sv genetic background) and wild-type littermates 
were identified by PCR genotyping using primers amplifying the mutant, 
5-ATAGCCTGAAGAACGAGATCA-3  and  5-GCTTCCAGAGAAATGC-
CACA-3,  and  wild-type,  5-CAATACGGAGAAGCTGGAGA-3  and   
5-CCCACCACCAAGGACATGAA-3, alleles, respectively (Ranheim et al., 
2005). Isg15-deficient mice (C57BL/6 genetic background) and wild-type 
littermates were identified by PCR genotyping using primers amplifying   
the mutant, 5-CGCGAAGGGGCCAACCAAAGAA-3 and 5-AGCCCC-
GATGAGGATGAGGTGT-3,  and  wild-type,  5-GCCCCCATCCAGAGC-
CAGTGTT-3  and  5-AGCCCCGATGAGGATGAGGTGT-3,  alleles, 
respectively (Osiak et al., 2005). Lrp5-deficient mice (C57BL/6 genetic 
background) were obtained from The Jackson Laboratory (005823). To 
determine the bone formation rate, all mice received two calcein injec-
tions, 9 and 2 d before sacrifice. For the histological analysis of eyeballs, 
we performed hematoxylin/eosin staining of paraffin sections according 
to standard protocols.
Skeletal analysis
Before  their  skeletal  analysis,  all  mice  (genetic  background  C57BL/6)   
received two injections of calcein (9 and 2 d before sacrifice). After their 
initial analysis by contact x ray (Cabinet X-ray System; Faxitron X-ray Cor-
poration), the vertebral bodies L2 to L5 and one tibia from each animal 
were dehydrated and embedded nondecalcified into methylmetacrylate 
for sectioning. Sections were either stained with toluidine blue or by the 
von Kossa/van Gieson procedure as previously described (Huebner et al., 
2006). Static and cellular histomorphometry was performed on toluidine 
blue–stained sections using the OsteoMeasure system (Osteometrics) fol-
lowing the guidelines of the American Society of Bone and Mineral   
Research (Parfitt et al., 1987). Dynamic histomorphometry for the determi-
nation of the bone formation rate was performed on two consecutive non-
stained 12-µm sections. TRAP activity staining was performed on decalcified 
sections using naphthol AS-MX phosphate (Sigma-Aldrich) and Fast Red   
Violet LB Salt (Sigma-Aldrich) in 40 mM acetate buffer, pH 5. All histological 
images  were  captured  at  room  temperature  using  a  microscope  (Axio 
Scope; Carl Zeiss, Inc.) with a 1.25× (no medium; 0.035 NA), 20× (no 
medium; 0.045 NA), or 40× (no medium; 0.75 NA) objective fitted with 
a camera (AxioCam; Carl Zeiss, Inc.). Image acquisition was performed 
using Axiovision software (Carl Zeiss, Inc.). The cortical thickness of fem-
ora was quantified by µCT scanning using a µCT 40 (Scanco Medical). 
Biomechanical stability of the femora was determined by three point–bending 
assays, whereas maximum strength and overall stiffness of the vertebrae 
were  determined  by  microcompression  testing  (Schinke  et  al.,  2009).   
The rate of bone resorption was determined by measuring the amount of 
bone-specific collagen degradation products (CrossLaps) in the serum   
(AC-06F1; Immunodiagnostic Systems).
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of the currently available antiosteoporotic therapies. In addi-
tion, if future studies will provide further evidence for a role of 
FZD9 as a positive regulator of bone formation in humans, 
FZD9 itself could be considered as a target for osteoanabolic 
therapy. In fact, because FZD proteins are serpentine receptors, 
thus belonging to the major class of target proteins for currently 
available drugs (Wise et al., 2002; Overington et al., 2006), it 
might be possible to develop FZD9-specific agonists and to ana-
lyze them for bone anabolic activity. In this regard, it is again 
relevant that Fzd9 controls osteoblast function without affecting 
the canonical Wnt signaling pathway because recent evidence 
suggested that increased levels of -catenin in osteoblasts cause 
a higher susceptibility to osteosarcoma development (Kansara 
et al., 2009).
Materials and methods
Cell culture
Primary osteoblasts were isolated from the calvariae of 5-d-old mice by 
sequential collagenase digestion as described previously (Schmidt et al., 
2005). Differentiation was induced by the addition of 50 µg/ml ascor-
bate and 10 mM -glycerophosphate. Total RNA was isolated using the 
TRIZOL reagent (Invitrogen) and further purified with the RNeasy Mini kit 
(QIAGEN). Proteins were isolated by cell lysis with radioimmunoprecipi-
tation assay buffer (1% NP-40, 1% sodium desoxycholate, 0.1% sodium 
dodecylsulfate, 150 mM sodium chloride, 2 mM EDTA, and 10 mM   
sodium phosphate) containing a protease and phosphatase inhibitor cock-
tail (Roche). Proliferation rates were measured by BrdU incorporation as-
says using the Biotrak Cell Proliferation kit (GE Healthcare), and matrix 
mineralization was assessed using von Kossa staining or alizarin red 
staining as previously described (Eferl et al., 2004; Schmidt et al., 2005). 
To analyze the effects of Wnt and interferon ligands, cells were serum 
starved overnight and then stimulated for 30 min or 6 h by the addition 
of 100 ng/ml Wnt3a (1324-WN-002; R&D Systems), 100 ng/ml Wnt5a 
(645-WN-010; R&D Systems) 100 ng/ml Ifn- (300-02A; PeproTech), or 
100  ng/ml  Ifn-  (300-02BC;  PeproTech).  Retroviral  vector  production 
and transductions for Isg15 expression were performed essentially as 
previously described (Guerra et al., 2008). Bone marrow–derived osteo-
blasts and osteoclasts were generated and analyzed as described previ-
ously (Huebner et al., 2006).
Expression analysis
For the genome-wide expression analysis, 5 µg RNA was used for first-
strand cDNA synthesis. Synthesis of biotinylated cRNA was performed   
using the IVT Labeling kit (Affymetrix). For GeneChip hybridization, the 
fragmented cRNA was incubated in hybridization solution at 45°C for   
16 h before the GeneChips (U74v2A and MG-430 2.0; Affymetrix) were 
washed using the Fluidics Station 450 (Affymetrix). Microarrays were scanned 
with the GeneChip scanner (Scanner 7G; Affymetrix), and the signals were 
processed using GeneChip Operating Software (Affymetrix). Absolute and 
comparative analyses were performed using the Microarray Suite algo-
rithm (Affymetrix). Annotations were further analyzed with interactive query 
analysis (Affymetrix). For RT-PCR expression analysis, 1 µg RNA was re-
versed transcribed using SuperScript III (Invitrogen) according to the manu-
facturer’s instructions. Gene-specific primers were used to amplify Fzd9, 
5-AGTTTCCTCCTGACCGGTTT-3 and 5-GTGGCAGCAGTACATGGTTG-3,   
and Gapdh, 5-GACATCAAGAAGGTGGTGAAGCAG-3 and 5-CTCCT-
GTTATTATGGGGGTCTGG-3. For in situ hybridization, the Fzd9-specific 
fragment was subcloned into pBluescript (Agilent Technologies) to generate 
[
35S]UTP-labeled  riboprobes  using  the  Riboprobe  Combination  System 
(Promega). qRT-PCR was performed using a StepOnePlus system (Applied 
Biosystems) and predesigned gene expression assays (TaqMan; Applied 
Biosystems) for Fzd9, Ibsp, Alpl, Tnfrsf11b, Apcdd1, Axin2, Oasl2, Ifit1, 
Isg15, Ccl5, Cxcl5, Ccl2, and Stat1. Gapdh and B2m expressions were 
used as internal controls. Relative quantification was performed according 
to the CT method.
Western blotting
For Western blotting, equal amounts of protein were subjected to SDS-
PAGE and then transferred to polyvinylidene fluoride membranes (Hybond; 1071 Fzd9 and bone formation • Albers et al.
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